About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

WITHDRAWNNCT00284440

Choroidal Blood Flow Response to Hand-grip Test in Progressive Glaucoma

The present study is designed to compare the response of choroidal blood flow to the hand-grip test in glaucoma patients with and without visual field progression.

Lead sponsor: University Hospital, Basel, Switzerland•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

University Hospital, Basel, Switzerland

Glaucoma is a worldwide leading cause of blindness. The key features of glaucoma are damage to the optic nerve head and progressive visual field defect, which is not necessarily only related to an increase in intraocular pressure. It has been suggested that ocular blood flow alterations in glaucoma are related to systemic vascular dysregulations.The hand-grip test has been suggested as a potential tool to unravel vascular dysregulation in the ocular circulation. Although applied routinely in clinical practice, a proper study testing the effectiveness of this test is lacking. The present study is designed to compare the response of choroidal blood flow to the hand-grip test in glaucoma patients with and without visual field progression.

Age

30 - 80 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•\-

Exclusion Criteria

•Ametropia \> 3dpt
•Inadequate transparency of ocular media as defined by physical examination
•Iridocorneal angle extremely narrow with complete or partial closure as determined by gonioscopy
•Any abnormality which in the physician's view would prevent reliable applanation tonometry or LDF of at least one eye
•History of chronic or recurrent severe inflammatory eye disease such as scleritis or uveitis
•History of ocular trauma or intraocular surgery within the past 6 months
•History of infection or inflammation within the past 3 months
•History of clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy or retinal detachment
•Patients with a significant history and/or active alcohol or drug abuse (significant is defined as that which in the opinion of the investigator may either put the patient at risk because of participation in the study or may influence the results of the study or the patient's ability to participate in the study).

Related studies

DSLT for Reducing Medication in Glaucoma

NCT07390890 · Primary Open Angle Glaucoma, Ocular Hypertension

Clinical Study Evaluating the Safety and Performance of the MIST Device for Intraocular Pressure Reduction in Patients With Primary Open-Angle Glaucoma

NCT07358650 · Primary Open Angle Glaucoma

Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population

NCT05902871 · Primary Open Angle Glaucoma, Ocular Hypertension, and more

A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients

NCT07076303 · Primary Open Angle Glaucoma, Glaucoma, and more

RECRUITINGPhase 4

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT

NCT06865144 · Primary Open Angle Glaucoma or Ocular Hypertension

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 10, 2015Terms

Trial snapshot

StatusWITHDRAWN

Phase—

Enrollment—

Start dateMar 2006

Last updatedMar 10, 2015

Condition

Primary Open Angle Glaucoma

Locations shown

University Eye Clinic

Basel, Canton of Basel-City

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 10, 2015Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions